Ji-Xin Cheng, co-founder and president of Vibronix Inc., said one challenge that physicians face is that the severity and location of a patient’s heart disease cannot be precisely tracked with traditional diagnostic tools.
“There are no methods to quantify the amount of lipids inside the arterial wall. These lipids, caused by cholesterol, build on the wall and slow down or block blood flow to the heart. A heart attack results when blood supply to the heart is completely blocked,” said Cheng, who is a Purdue professor of biomedical engineering and chemistry. “There also are no methods to locate where lipids are located. If a person with chest pain visits a cardiologist, the cardiologist may give a stint that releases the pain, but it doesn’t reduce the probability of a heart attack.”
Purdue researchers led by Cheng have developed technology that could help cardiologists better understand the severity and location of plaque buildup on arterial walls. The technology has been licensed to Vibronix through the Purdue Office of Technology Commercialization. More than 20 startups based on Purdue intellectual property were launched in the 2014 fiscal year. A video about Vibronix is available at http://youtu.be/Min7qjanJOQ.
Pu Wang, who was a doctoral student in Cheng’s laboratory when the technology was discovered, is Vibronix’s chief technology officer. He said the company has developed an intravascular sensor that is inserted into the femoral artery using a common procedure to identify stressors on the heart.
“The sensor, which is around one millimeter in size, emits light onto the arterial wall. Only the lipid component inside the arterial wall responds to the light. It emits acoustic signals that are detected by the sensor and sent to another system,” Wang said. “We rotate and pull back the sensor in the artery, which creates a three-dimensional view that shows where high-density lipid sections have developed on the arterial wall.”
Wang said Vibronix’s sensor technology also could help researchers and contract research organizations develop new treatments for heart disease and determine the efficacy for currently available treatments.
Cheng said Vibronix will focus on validating the technology by working with research and industrial partners on the beta prototype.
“We will need to raise money for additional work, and we are looking for a chief executive officer who will lead the company’s business side,” he said.
For information on other Purdue intellectual property ready for licensing and commercialization, visit http://www.otc-prf.org. For more information about available leadership positions, investing in a Purdue startup or licensing a Purdue innovation, visit http://www.purduefoundry.com.
Early validations in Ji-Xin Cheng’s lab at Purdue University led to the founding of Vibronix. Vibronix was co-founded by Cheng and Pu Wang, his student, to commercialize the technologies discovered in Cheng’s lab. The company was formed with the support of the Purdue Foundry program, an entrepreneurship and commercialization hub at Purdue University. The Foundry will continue to serve in a business advisory role throughout the commercialization process as will the Office of Technology and Commercialization and the Purdue Research Foundation.
About Purdue Office of Technology Commercialization
The Purdue Office of Technology Commercialization operates one of the most comprehensive technology-transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university’s academic activities. The office is managed by the Purdue Research Foundation, which received the 2014 Incubator Network of the Year from the National Business Incubation Association for its work in entrepreneurship. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at firstname.lastname@example.org.
Purdue Research Foundation contact: Steve Martin, 765-588-3342, email@example.com
Sources: Ji-Xin Cheng, 765-494-4335, firstname.lastname@example.org
Pu Wang, email@example.com
Note to journalists: Here is a link to a video that accompanies this story. http://youtu.be/Min7qjanJOQ